A detailed history of Alkeon Capital Management LLC transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Alkeon Capital Management LLC holds 2,743,505 shares of CRBU stock, worth $7.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,743,505
Previous 3,113,564 11.89%
Holding current value
$7.9 Million
Previous $17.8 Million 20.96%
% of portfolio
0.02%
Previous 0.04%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$4.82 - $8.26 $1.78 Million - $3.06 Million
-370,059 Reduced 11.89%
2,743,505 $14.1 Million
Q4 2023

Feb 13, 2024

BUY
$3.58 - $6.25 $5.26 Million - $9.18 Million
1,468,701 Added 89.29%
3,113,564 $17.8 Million
Q3 2023

Nov 13, 2023

BUY
$4.08 - $8.14 $1.17 Million - $2.34 Million
287,800 Added 21.21%
1,644,863 $7.86 Million
Q2 2023

Aug 11, 2023

BUY
$4.04 - $5.47 $1.22 Million - $1.65 Million
302,418 Added 28.67%
1,357,063 $5.77 Million
Q1 2023

May 12, 2023

SELL
$4.3 - $7.78 $17,019 - $30,793
-3,958 Reduced 0.37%
1,054,645 $5.6 Million
Q4 2022

Feb 13, 2023

SELL
$5.57 - $11.01 $910,628 - $1.8 Million
-163,488 Reduced 13.38%
1,058,603 $6.65 Million
Q3 2022

Nov 10, 2022

BUY
$5.34 - $12.79 $1.86 Million - $4.46 Million
348,542 Added 39.9%
1,222,091 $12.9 Million
Q2 2022

Aug 15, 2022

SELL
$5.1 - $9.74 $1.78 Million - $3.41 Million
-350,000 Reduced 28.61%
873,549 $4.74 Million
Q1 2022

May 16, 2022

SELL
$8.42 - $15.32 $194,299 - $353,524
-23,076 Reduced 1.85%
1,223,549 $11.2 Million
Q3 2021

Nov 15, 2021

BUY
$15.75 - $30.29 $19.6 Million - $37.8 Million
1,246,625 New
1,246,625 $29.8 Million

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $175M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Alkeon Capital Management LLC Portfolio

Follow Alkeon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alkeon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alkeon Capital Management LLC with notifications on news.